- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03556085
Venous Sinus Stenting With the River Stent in IIH
Clinical Evaluation of the Serenity River Stent System to Treat Idiopathic Intracranial Hypertension
The objective of the study is to show that stenting the transverse-sigmoid sinus with the River stent is safe and has probable benefit to relieve clinical symptoms in subjects with idiopathic intracranial hypertension (IIH).
The study will enroll 39 IIH subjects with moderate to severe visual field loss or severe headaches that have failed medical therapy.
The primary safety endpoint is the rate of major adverse event at 12 months The primary probable benefit endpoint is a composite at 12 months of absence of significant sinus stenosis and clinically relevant improvement.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study objective: The objective of the study is to show that stenting the transverse-sigmoid sinus with the River stent is safe and has probable benefit to relieve clinical symptoms in subjects with idiopathic intracranial hypertension (IIH)
Investigational product: Serenity River Stent System
Study design: prospective, multicenter, single arm, open label clinical trial
Subject population: IIH subjects with significant (>50%) stenosis of the transverse-sigmoid sinuses and moderate to severe visual field loss or severe headaches that have failed medical therapy. In the absence of this trial, subjects would have been offered a surgical treatment of IIH such as sinus stenting with an off-label device, cerebrospinal fluid shunting, or optic nerve sheath fenestration by the treating physician.
- For subjects with visual field loss: if moderate to severe visual field loss (mean deviation between -6db and -30 db) for at least 2 weeks despite escalation of acetazolamide to 1000 mg twice a day or if the visual field deteriorates by more than 2 db during treatment, or treatment intolerance.
- For subjects with headaches: if they have severe headaches (HIT > 59) for at least 4 weeks despite treatment with topiramate 100 mg twice a day or other headache medication, or treatment intolerance.
Enrollment size and sites: 39 subjects will be enrolled in up to 10 US sites.
Primary safety endpoint: Major Adverse Event at 12 months. The MAE is a composite of the following: moderate or severe stroke (NIHSS > 3), neurological death, perforation or thrombosis of sinus or cerebral vein, device distal embolization, need for target lesion revascularization or need for alternate IIH surgical procedure such as cerebrospinal fluid shunting or optic nerve sheath fenestration.
Primary probable benefit endpoint: a composite at 12 months of:
- Absence of significant (>50%) stenosis of the stented sinus on retrograde catheter venography and
- Trans-stent pressure gradient < 8 mm Hg and
Clinically relevant improvement in the main clinical outcome per specific inclusion criteria and stabilization or better of the other:
- Headaches: if the specific inclusion criteria was headaches, improvement in the HIT- 6 scale by > 4 points and improvement or stabilization of visual field.
- Ophthalmic: if the specific inclusion criteria was visual field loss, improvement of visual field by > 29% of the baseline value in the study eye, stabilization or improvement in the fellow eye, and improvement or stabilization of headaches.
Study duration and follow-up: The subjects will be followed at 2 weeks, 3 months, 6 months and 12 months. At 12 months, clinical examination, lumbar puncture and retrograde catheter venography with manometry will be performed to evaluate the patency of the treated sinus and the absence of trans-stent pressure gradient. Subjects will be consented to be clinically followed annually for up to 5 years.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Florida
-
Jacksonville, Florida, United States, 32207
- Baptist Health
-
-
New York
-
Buffalo, New York, United States, 14203
- UB Neurosurgery
-
Manhasset, New York, United States, 11030
- Northwell Health
-
New York, New York, United States, 10065
- Weill Cornell Medicine
-
-
North Carolina
-
Winston-Salem, North Carolina, United States, 27157
- Wake Forest University Health Sciences
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Oregon Health & Science University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Subjects must meet all of the following criteria to be eligible for participation in the study:
- Subject is > 18 year-old and has given informed consent.
- Diagnosis of IIH per Modified Dandy Criteria.
- CSF opening pressure is > 25 cm H2O.
- Radiological examination (magnetic resonance venography (MRV) or computed tomographic venography (CTV)) shows bilateral transverse-sigmoid venous sinus stenosis (> 50%) or unilateral stenosis of the dominant sinus with contralateral hypoplastic sinus.
- Presence of IIH clinical symptoms (6. OR 7.)
- Headaches: Score > 59 (severe impact) on the HIT-6 scale, refractory to medical therapy (e.g. acetazolamide 1000 mg twice daily, topiramate 100 mg twice daily, or other headache medication) for ≥ 4 weeks, or treatment intolerance OR
- Visual field loss: defined by perimetric mean deviation (PMD) between -6 dB and -30 dB in one or both eyes (with papilledema Grade >1) despite at least 2 weeks of medical therapy with acetazolamide 1000 mg twice daily, or if the visual field deteriorates by more than 2 dB during treatment, or treatment intolerance.
- In the absence of this study, the subject would have been offered a surgical intervention by Optic Nerve Sheath Fenestration (ONSF), Cerebro Spinal Fluid (CSF) shunting procedure, or venous sinus stenting with an off-label device.
- Catheter manometry shows a pressure gradient > 8 mm Hg across the transverse sigmoid sinus stenosis.
- Venographic evidence of sinus stenosis (> 50%)
Exclusion Criteria:
Subject must be excluded from participation in this study if any of the following criteria are met
- Subjects presenting with de novo papilledema and severe visual field(VF) deficit (VF loss > -15db) that requires immediate surgical treatment without prior attempt of medical therapy.
- Currently has or plans to have an implanted CSF shunt.
- History of previously implanted intra-cranial sinus stent.
- Transverse-sigmoid sinus vessel size <5 mm or >10 mm.
- Creatinine > 1.5 mg/dl and/or creatinine clearance < 60 mL/min (except if patients is already on hemodialysis).
- Allergic to imaging contrast media (iodine or gadolinium) despite premedication.
- Allergic to nitinol or nickel.
- Contra-indication to general anesthesia.
- Contra-indication to aspirin, clopidogrel or other anticoagulant.
- Hypercoagulable state (Factor V Leiden, Protein C or S deficiency, Anticardiolipin antibodies, Lupus anticoagulant, B2-glycoprotein-1 antibodies, or Hyperhomocysteinemia).
- Currently requiring full anti-coagulation for other medical reasons, such as atrial fibrillation (AF), artificial valves, deep vein thrombosis pulmonary embolism, etc.
- History of stroke or transient ischemic attack (TIA).
- History of AF or other risks of stroke.
- History of deep vein thrombosis or pulmonary embolism.
- History of severe chronic obstructive pulmonary disease or other severe respiratory disease.
- History of severe carotid atherosclerotic disease.
- History of heart failure, dilated cardiomyopathy, or congenital heart conditions, etc. that are at high thrombogenic risk.
- History of uncontrolled diabetes.
- Use (oral) of tetracycline derivative, retinoid or vitamin A during the last 3 months.
- Cerebral vascular lesions (arteriovenous malformation (AVM), arteriovenous fistula, aneurysms, significant stenosis of extra- or intra-cranial vessels other than the targeted venous sinus stenosis,intracranial artery dissection, etc.).
- Patient has visions loss due to other disease (e.g. cataract, macular degeneration, glaucoma, etc.).
- Inability to provide reliable and reproducible visual field examinations (>15% false positive errors and/or failure to maintain fixation for eye monitoring).
- For female subject of child bearing potential, pregnant or not willing to use contraception for 12 months.
- Presence of a physical, mental or social condition that could prevent adequate one-year follow-up (homelessness, drug dependency, anticipation of moving far away, life threatening disease, terminal illness).
- Anatomical anomaly of the venous sinus which would prevent safe catheterization and stenting (e.g multi-channel sinus)
- Currently enrolled in a premarket investigational study. Enrollment in a post market study that does not impact the River™ Stent procedure or device is allowed.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Venous sinus stenting
Subjects will have stenting of the transverse-sigmoid sinus
|
Patient is placed under general anesthesia.
From femoral vein access, a standard guide-catheter is advanced in the internal jugular vein (on the side considered for stenting).
The sigmoid then transverse sinus is catheterized with a microcatheter and guide-wire and an exchange guide-wire is placed in the superior sagittal sinus.
The River stent delivery catheter is advanced over the exchange guide-wire in the sigmoid then transverse sinus up to the torcula.
The River stent is deployed to cover the entire transverse sinus and the proximal half of the sigmoid sinus.
The catheters are removed and hemostasis obtained by using a closure device or manual compression.
The patient is kept overnight in the hospital for observation.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Major Adverse Event (MAE)
Time Frame: 12 months
|
The MAE is a composite of the following: Moderate or severe stroke (NIH stroke scale > 3) Neurological death Perforation of sinus or cerebral vein Thrombosis of sinus or cerebral vein Device distal embolization Need for target lesion revascularization or need for IIH alternate procedure (cerebrospinal fluid shunting or optic nerve sheath fenestration) |
12 months
|
Clinical improvement with no restenosis of the venous sinus
Time Frame: 12 months
|
The primary probable benefit endpoint is a composite of:
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Individual components of MAE.
Time Frame: 12 months
|
Components of MAE will be reported as individual event rates.
|
12 months
|
Cerebrospinal fluid (CSF) opening pressure at 12 months
Time Frame: 12 months
|
CSF opening pressure will be measured via lumbar puncture in the lateral decubitus position.
|
12 months
|
Stent patency at 12 months
Time Frame: 12 months
|
Stent patency will be assessed by retrograde catheter venography.
Patency is defined as absence of significant (>50%) stenosis
|
12 months
|
Medications
Time Frame: 12 months
|
Change in IIH medications and dosage at 12 months compared to baseline
|
12 months
|
Headaches
Time Frame: 12 months
|
Change in headaches assessed using the Headache Impact Test (HIT-6) scale (minimum score 36, maximum 78; higher value represents worse headache) at 12 months compared to baseline.
|
12 months
|
Papilledema
Time Frame: 12 months
|
Change in papilledema grading using Frisen scale (Stage 0 to 5; stage 0 represents no papilledema and is the best outcome) at 12 months compared to baseline.
|
12 months
|
Visual acuity
Time Frame: 12 months
|
Change in visual acuity using the Early treatment Diabetic Retinopathy (ETDRS) chart at 12 months compared to baseline.
|
12 months
|
Retinal Nerve Fiber Layer Thickness
Time Frame: 12 months
|
Change in retinal nerve fiber layer thickness measured using Optical Coherence Tomography (OCT) at 12 months compared to baseline.
|
12 months
|
Tinnitus
Time Frame: 12 months
|
Change in the intensity of tinnitus evaluated on the Tinnitus Functional Index (TFI) score (overall score; minimum 0, maximum 100; 100 is the worst tinnitus with the worst negative impact) at 12 months compared to baseline.
|
12 months
|
Quality of Life SF-12
Time Frame: 12 months
|
Change in quality of life assessed with the Short Form health survey 12 items (SF-12) at 12 months compared to baseline
|
12 months
|
Quality of Life NEI-VFQ-25
Time Frame: 12 months
|
Change in quality of life assessed with the National Eye Institute - Visual Functioning Questionnaire - 25 at 12 months compared to baseline.
|
12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Athos Patsalides, MD, Northwell Health
Publications and helpful links
General Publications
- Albuquerque FC, Gross BA, Levitt MR. Time to re-assess the treatment of idiopathic intracranial hypertension. J Neurointerv Surg. 2016 Jun;8(6):549-50. doi: 10.1136/neurintsurg-2016-012460. No abstract available.
- Abubaker K, Ali Z, Raza K, Bolger C, Rawluk D, O'Brien D. Idiopathic intracranial hypertension: lumboperitoneal shunts versus ventriculoperitoneal shunts--case series and literature review. Br J Neurosurg. 2011 Feb;25(1):94-9. doi: 10.3109/02688697.2010.544781.
- Aguilar-Perez M, Martinez-Moreno R, Kurre W, Wendl C, Bazner H, Ganslandt O, Unsold R, Henkes H. Endovascular treatment of idiopathic intracranial hypertension: retrospective analysis of immediate and long-term results in 51 patients. Neuroradiology. 2017 Mar;59(3):277-287. doi: 10.1007/s00234-017-1783-5. Epub 2017 Mar 2.
- Ahmed RM, Wilkinson M, Parker GD, Thurtell MJ, Macdonald J, McCluskey PJ, Allan R, Dunne V, Hanlon M, Owler BK, Halmagyi GM. Transverse sinus stenting for idiopathic intracranial hypertension: a review of 52 patients and of model predictions. AJNR Am J Neuroradiol. 2011 Sep;32(8):1408-14. doi: 10.3174/ajnr.A2575. Epub 2011 Jul 28.
- Dinkin MJ, Patsalides A. Venous Sinus Stenting in Idiopathic Intracranial Hypertension: Results of a Prospective Trial. J Neuroophthalmol. 2017 Jun;37(2):113-121. doi: 10.1097/WNO.0000000000000426.
- Kanagalingam S, Subramanian PS. Cerebral venous sinus stenting for pseudotumor cerebri: A review. Saudi J Ophthalmol. 2015 Jan-Mar;29(1):3-8. doi: 10.1016/j.sjopt.2014.09.007. Epub 2014 Sep 27.
- Dinkin MJ, Patsalides A. Venous Sinus Stenting for Idiopathic Intracranial Hypertension: Where Are We Now? Neurol Clin. 2017 Feb;35(1):59-81. doi: 10.1016/j.ncl.2016.08.006.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- River 1111-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Idiopathic Intracranial Hypertension
-
St. Joseph's Hospital and Medical Center, PhoenixBarrow Neurological InstituteRecruitingPseudotumor Cerebri | Idiopathic Intracranial Hypertension (IIH)United States
-
Weill Medical College of Cornell UniversityCompletedIdiopathic Intracranial Hypertension (IIH)United States
-
Assiut UniversityNot yet recruitingIIH - Idiopathic Intracranial Hypertension
-
Hillel Yaffe Medical CenterUnknownPediatric Idiopathic Intracranial HypertensionIsrael
-
Beijing Tiantan HospitalRecruitingVenous Sinus Stenosis | Idiopathic Intracranial HypotensionChina
-
Integra LifeSciences CorporationAvaniaCompletedHydrocephalus | NPH (Normal Pressure Hydrocephalus) | IIH - Idiopathic Intracranial HypertensionGermany, Netherlands
-
Danish Headache CenterOdense University HospitalRecruitingBenign Intracranial HypertensionDenmark
-
Mayo ClinicNational Eye Institute (NEI)RecruitingIdiopathic Intracranial HypertensionUnited States
-
Assiut UniversityRecruiting
-
Centre Hospitalier Universitaire, AmiensRecruitingIntracranial HypertensionFrance
Clinical Trials on Venous sinus stenting (Serenity River)
-
Weill Medical College of Cornell UniversityCompletedIdiopathic Intracranial Hypertension (IIH)United States
-
Al-Azhar UniversityEnrolling by invitationIdiopathic Intracranial HypertensionEgypt
-
Fondation Ophtalmologique Adolphe de RothschildRecruitingPseudotumor Cerebri | Cerebrospinal Fluid | Transverse SinusesFrance
-
Ottawa Hospital Research InstituteUnknownIdiopathic Intracranial HypertensionCanada
-
Weill Medical College of Cornell UniversityTerminatedTinnitus | Pulsatile Tinnitus | Venous Sinus Stenosis | Dural Sinus StenosisUnited States
-
Maastricht University Medical CenterTerminatedRandomized Clinical Trial | Deep-Venous Thrombosis | Deep Venous StentingNetherlands
-
be MedicalArcher ResearchWithdrawnVenous Vascular Diseases and SyndromesBelgium
-
Capital Medical UniversityUnknownHeadache | Intracranial Hypertension | Tinnitus | Visual Impairment | Stent Stenosis | Papilledema
-
Ji Xunming,MD,PhDRecruitingCerebral Venous Sinus ThrombosisChina
-
St. Joseph's Hospital and Medical Center, PhoenixBarrow Neurological InstituteRecruitingPseudotumor Cerebri | Idiopathic Intracranial Hypertension (IIH)United States